Bladder cancer treatment: therapy vs. surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two standard treatments for high-grade non-muscle-invasive bladder cancer that has come back after initial treatment: medication placed directly into the bladder (intravesical therapy) or bladder removal surgery (cystectomy). The goal is to see which option works better for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of bladder cancer called high-grade non-muscle-invasive bladder cancer (NMIBC), confirmed by a biopsy showing stages Tis, Ta, or T1.
- At least half of the cancer cells examined are a common type called urothelial carcinoma.
- You have had this type of bladder cancer before and it has come back.
- In the past 12 months, you received at least one dose of bladder medication (intravesical therapy) or systemic therapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.
This trial tests giving chemotherapy before surgery to remove the bladder, to see if it can improve outcomes for patients with muscle-invasive bladder cancer. The treatment is personalized based on a lab test of your tumor cells, which may help make the therapy more effective.
This study tests a newer way to remove bladder tumors (called ERBT) combined with BCG, a standard immunotherapy placed in the bladder, for people with bladder cancer that is not too advanced. The goal is to see if this combination helps reduce the chance of the cancer coming back.
This study looks at whether removing nearby lymph nodes during radical cystectomy (bladder removal) improves outcomes for people with high-risk non–muscle-invasive bladder cancer. It may help doctors choose the best surgical approach to reduce the chance of cancer coming back.
This study tests a new medicine called Alpha1H that is given before the usual surgery to remove bladder cancer. It may help lower the risk of the cancer coming back.
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.